Evidence map›Paper›PMID 42298912›Full record

ArticleClinical and translational medicine2026

PPP2R3C serves as a negative regulator associated with reduced T cell hyperactivation and renal protection in lupus.

Xuan Fang, Yi Qin, Jinhui Tao, Zhou Zhou, Minglong Cai, Hong Zhang, Xiangpei Li, Xiaomei Li, Zhu Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xuan FangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
Yi QinDepartment of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Jinhui TaoDepartment of Allergy and Clinical Immunity, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.ORCID 0000-0003-4904-033X
Zhou ZhouDepartment of Nephrology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
Minglong CaiDepartment of Dermatology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
Hong ZhangDepartment of Laboratory Medicine, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
Xiangpei LiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
Xiaomei LiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.ORCID 0000-0002-3103-2596
Zhu ChenDepartment of Rheumatology and Immunology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.ORCID 0000-0003-0828-1583

Funding

Anhui Provincial Health Research Foundation AHWJ2023A10120Anhui Provincial Natural Science Foundation 2408085J046Anhui Provincial Natural Science Foundation 2408085QH257National Natural Science Foundation of China 81671601National Natural Science Foundation of China 82471819National Natural Science Foundation of China U21A20365
6 · The paper itself

Abstract

backgroundCD4

methodsPPP2R3C expression was measured by qRT-PCR and Western blotting in CD4

resultsWe identified the protein phosphatase 2A regulatory subunit PPP2R3C as a critical and selective negative regulator of T cell receptor (TCR) signaling, which was downregulated in CD4

conclusionsOur findings identify PPP2R3C as an important contributor to SLE pathogenesis and support its restoration as a gene therapy approach worthy of further exploration for its ability to rebalance immunity and mitigate tissue injury in SLE. KEY POINTS: PPP2R3C is selectively downregulated in SLE CD4

Indexed as

KidneyLupus Erythematosus, SystemicLymphocyte ActivationProtein Phosphatase 2AnimalsDisease Models, AnimalFemaleHumansMiceProtein Phosphatase 2gene therapyPPP2R3Csystemic lupus erythematosusT cell hyperactivation

Identifiers

PMID42298912
PMCPMC13269831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.